LU88806I2 - NovoSeven R Eptacog alfa (activated) - Google Patents

NovoSeven R Eptacog alfa (activated)

Info

Publication number
LU88806I2
LU88806I2 LU88806C LU88806C LU88806I2 LU 88806 I2 LU88806 I2 LU 88806I2 LU 88806 C LU88806 C LU 88806C LU 88806 C LU88806 C LU 88806C LU 88806 I2 LU88806 I2 LU 88806I2
Authority
LU
Luxembourg
Prior art keywords
factor
protein
encoding
sequence
novoseven
Prior art date
Application number
LU88806C
Other languages
English (en)
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of LU88806I2 publication Critical patent/LU88806I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Retarders (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
LU88806C 1985-04-17 1986-04-16 NovoSeven R Eptacog alfa (activated) LU88806I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431185A 1985-04-17 1985-04-17
US06/810,002 US4784950A (en) 1985-04-17 1986-12-16 Expression of factor VII activity in mammalian cells

Publications (1)

Publication Number Publication Date
LU88806I2 true LU88806I2 (fr) 1997-01-03

Family

ID=27110961

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88806C LU88806I2 (fr) 1985-04-17 1986-04-16 NovoSeven R Eptacog alfa (activated)

Country Status (18)

Country Link
US (1) US4784950A (fr)
EP (1) EP0200421B1 (fr)
JP (4) JPH0824587B2 (fr)
CN (1) CN1032142C (fr)
AT (1) ATE92105T1 (fr)
AU (1) AU603983B2 (fr)
CA (1) CA1340512C (fr)
DE (1) DE3688760T2 (fr)
DK (2) DK175616B1 (fr)
ES (1) ES8800343A1 (fr)
FI (1) FI100055B (fr)
GR (1) GR860984B (fr)
HU (1) HU204556B (fr)
IE (1) IE61982B1 (fr)
LU (1) LU88806I2 (fr)
NO (3) NO175066B (fr)
NZ (1) NZ215842A (fr)
PT (1) PT82408B (fr)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
JPH0780783B2 (ja) * 1985-11-26 1995-08-30 ノボ ノルディスク アクティーゼルスカブ 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物
IL82648A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Human protein s,a plasma protein regulator of hemostasis
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) * 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
EP0289586A4 (fr) * 1986-11-17 1990-04-10 New England Medical Ct Amelioration de la gamma-carboxylation de proteines recombinantes dependantes de la vitamine k.
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
DE4007902A1 (de) * 1990-03-13 1991-09-19 Behringwerke Ag Synthetische peptide, die sequenzen aus faktor viia enthalten und deren verwendung
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5876985A (en) * 1991-04-25 1999-03-02 Board Of Regents, The University Of Texas System Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5965350A (en) * 1994-04-08 1999-10-12 Syntex (U.S.A.) Inc. Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
DK1632574T3 (da) 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
WO1999003498A1 (fr) 1997-07-18 1999-01-28 Novo Nordisk A/S Utilisation de fvii ou fviiai pour le traitement de pathologies liees au processus de transmission des signaux intracellulaires induites par fviia
JP2002516061A (ja) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6159722A (en) * 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
EP0927764B1 (fr) * 1997-12-03 2004-05-26 Boehringer Mannheim Gmbh Serine protéases chimériques
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
CN1344320A (zh) 1998-09-23 2002-04-10 津莫吉尼蒂克斯公司 细胞因子受体zalphall
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
JP4739526B2 (ja) 1998-12-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド 成長因子相同体ｚｖｅｇｆ３
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CZ303272B6 (cs) 1999-01-07 2012-07-11 Zymogenetics, Inc. Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
CA2366921C (fr) 1999-03-09 2013-12-17 Zymogenetics, Inc. Nouvelle cytokine ligand zalpha11
ATE509028T1 (de) 1999-03-15 2011-05-15 Novo Nordisk As Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
EP1242600B1 (fr) 1999-12-23 2010-03-03 ZymoGenetics, Inc. La cytokine zcyto18
AU783512B2 (en) 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
EP2258725A3 (fr) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Récepteur de la cytokine zcytor17
EP1294888B1 (fr) 2000-06-30 2007-04-25 ZymoGenetics, Inc. Proteine zcyto21de type interferon
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
CA2420892A1 (fr) 2000-09-13 2002-03-21 Novo Nordisk A/S Variants du facteur vii de coagulation humaine
EP2253703A1 (fr) 2000-09-13 2010-11-24 Novo Nordisk Health Care AG Variantes de facteur VII de coagulation humaine
FR2814170B1 (fr) * 2000-09-18 2005-05-27 Rhodia Chimie Sa Nouveau latex a proprietes de surface modifiees par l' ajout d'un copolymere hydrosoluble a caractere amphiphile
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
KR100880624B1 (ko) 2000-10-02 2009-01-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 비타민 ｋ-의존 단백질의 생산 방법
WO2002055110A2 (fr) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AU2002244757A1 (en) * 2001-04-02 2002-10-15 Bayer Aktiengesellschaft Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
JP4353701B2 (ja) 2001-05-08 2009-10-28 ダーウィン モレキュラー コーポレイション Ｆｏｘｐ３蛋白質を用いた霊長類における免疫機能の調節方法
EP1432794B1 (fr) 2001-09-27 2011-11-09 Novo Nordisk Health Care AG Polypeptides de facteur vii de coagulation humain
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CN102180944A (zh) 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2005508179A (ja) 2001-11-05 2005-03-31 ザイモジェネティクス，インコーポレイティド Ｉｌ−２１アンタゴニスト
JP2005515175A (ja) * 2001-11-09 2005-05-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびアルファ２−抗プラスミンポリペプチドを含む薬学的組成物
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
EP1446153A1 (fr) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Composition pharmaceutique renfermant des polypeptides de facteur vii et des inhibiteurs du plasminogene tissulaire
BR0215216A (pt) * 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1463512B1 (fr) 2002-01-11 2014-05-28 biOasis Technologies Inc. Utilisation de p97 en tant que systeme d'administration d'enzymes en vue d'administrer des enzymes lysosomales therapeutiques
ES2377188T3 (es) 2002-01-18 2012-03-23 Zymogenetics, Inc. Nuevo ligando de citocina ZCYTOR17
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
CN101676728A (zh) 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 细胞因子受体
ATE488581T1 (de) * 2002-04-30 2010-12-15 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BRPI0311959B8 (pt) * 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
JP4634145B2 (ja) 2002-06-21 2011-02-16 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ペジル化されたｖｉｉ因子糖形体
US6933136B2 (en) * 2002-09-20 2005-08-23 Novo Nordisk A/S Method for making recombinant proteins
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1546202B1 (fr) 2002-09-25 2007-08-22 Novo Nordisk Health Care AG Polypeptides du facteur vii de coagulation humain
EP3103869A1 (fr) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Procédé de production de polypeptides de facteur vii
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
WO2004083361A2 (fr) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. Variants de fvii ou fviia
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
MXPA05013769A (es) * 2003-06-19 2006-03-08 Maxygen Holdings Ltd Variantes del dominio gla del factor vii o viia.
WO2004112828A1 (fr) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Composition liquide de polypeptides du facteur vii
WO2005002615A1 (fr) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Preparations pharmaceutiques aqueuses liquides de polypeptides facteur vii
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005044849A2 (fr) * 2003-08-05 2005-05-19 Eli Lilly And Company Proteines mammiferes lp; reactifs associes
EP1927600A1 (fr) 2003-08-07 2008-06-04 Zymogenetics, Inc. Propositions homogènes de IL-28 et IL-29
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
BRPI0416950B8 (pt) 2003-12-01 2021-05-25 Novo Nordisk Healthcare Ag métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
CA2552043A1 (fr) 2004-01-21 2005-08-04 Novo Nordisk A/S Conjugaison de peptides induite par la transglutaminase
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
CA2574564C (fr) 2004-07-29 2013-04-16 Zymogenetics, Inc. Utilisation des molecules il-28 et il-29 pour traiter le cancer et les troubles autoimmuns
DE602005021509D1 (de) * 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1831242B1 (fr) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction du contenu en contaminants proteiques de compositions renfermant une proteine d'interet dependante de la vitamine k
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
MX2007012704A (es) * 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
EP1728798A1 (fr) 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
EP1893632B1 (fr) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Reduction et derivation séléctives de proteines facteur vii comprenant au moins une cysteine non native
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
AR059025A1 (es) 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
JP2009507777A (ja) * 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007026021A1 (fr) 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Purification de polypeptides du facteur vii par chromatographie d'interaction hydrophobe
EP1926817A2 (fr) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Polypeptides du facteur vii de coagulation humain
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (fr) * 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
EP1820508A1 (fr) 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
WO2007104317A1 (fr) * 2006-03-16 2007-09-20 Drugrecure Aps Procedes de traitement local avec le facteur vii
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
JP2009533364A (ja) * 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法
EA015342B1 (ru) * 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
WO2007144173A1 (fr) 2006-06-14 2007-12-21 Csl Behring Gmbh Protéine de fusion pouvant subir un clivage protéolytique et contenant un facteur de coagulation sanguine
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (fr) 2006-06-14 2007-12-19 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
EP2059527B1 (fr) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Glycoprotéines modifiées
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CA2673757A1 (fr) 2006-11-30 2008-06-05 Tapimmune Inc. Traitement des poxviridae comportant tap-1 et/ou tap-2 en tant qu'adjuvant moleculaire
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
WO2008077616A1 (fr) * 2006-12-22 2008-07-03 Csl Behring Gmbh Facteurs de coagulation modifiés présentant une demi-vie in vivo prolongée
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
CN103451172A (zh) * 2007-04-13 2013-12-18 催化剂生物科学公司 修饰的因子vii多肽及其应用
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
US9359629B2 (en) 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
DK2274008T3 (da) 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2313105B1 (fr) 2008-06-27 2013-07-24 ZymoGenetics, Inc. RÉCEPTEURS Fc gamma HYBRIDES SOLUBLES ET PROCÉDÉS ASSOCIÉS
EP2356247B2 (fr) * 2008-11-12 2019-05-15 Baxalta Incorporated Procédé de production de facteur vii sans insuline, sans sérum
EP3243835B1 (fr) 2009-02-11 2024-04-10 Albumedix Ltd Variants et conjuges de l'albumine
FR2942231B1 (fr) 2009-02-19 2015-03-20 Lfb Biotechnologies Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
WO2010149172A2 (fr) 2009-06-24 2010-12-29 Rigshospitalet Effet pro-hemostatique systemique de facteurs de coagulation en combinaison avec des sympathicomimetiques a effets agonistiques sur des recepteurs α-adrenergiques et/ou β-adrenergiques du systeme nerveux, associe a une capacite de coagulation amelioree
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
EP2470559B1 (fr) 2009-08-24 2017-03-22 Amunix Operating Inc. Compositions de facteur ix de coagulation et leurs procédés de fabrication et d'utilisation
WO2011053738A1 (fr) * 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Procédé de production de protéines recombinantes dépendantes de la vitamine k
CA2776241A1 (fr) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Variants d'albumine
EP3715356B1 (fr) 2009-12-18 2023-10-11 CSL Limited Procédé de purification de polypeptides
WO2011124718A1 (fr) 2010-04-09 2011-10-13 Novozymes A/S Dérivés et variants d'albumine
BR112012031329A2 (pt) 2010-06-09 2016-10-11 Zymogenetics Inc proteínas de fusão diméricas vstm3 e composições e métodos relacionados
EP2633058B1 (fr) * 2010-10-26 2016-07-20 Hanmi Science Co., Ltd. Procédé de production à grande échelle du facteur vii/viia
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2013006706A1 (fr) 2011-07-05 2013-01-10 Bioasis Technologies Inc. Conjugués p97-anticorps et procédés d'utilisation
US8722019B2 (en) 2011-08-05 2014-05-13 Bioasis Technologies, Inc. P97 fragments with transfer activity
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
US9771576B2 (en) 2012-02-01 2017-09-26 Synthetic Genomics, Inc. Materials and methods for the synthesis of error-minimized nucleic acid molecules
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
WO2013123457A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Protéines de facteur viii de recombinaison
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
EP2687595B1 (fr) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Procédé de purification de facteur VII transgénique
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
JP2015534573A (ja) 2012-10-10 2015-12-03 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子ポリペプチドの液体医薬組成物
US20150259665A1 (en) 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
EP2906693A1 (fr) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Polypeptides de facteur vii de coagulation
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
EP2970433B1 (fr) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments de p97 et leurs utilisations
WO2014153205A1 (fr) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Dosage diagnostique des thymidine kinases pour applications de thérapie génique
AU2013204728B2 (en) 2013-03-15 2016-09-15 Baxalta GmbH Methods for treating bleeding disorders using a platelet subpopulation
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3102608B1 (fr) 2014-02-03 2019-09-18 Bioasis Technologies Inc. Protéines de fusion p97
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
CN106413757B (zh) 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 p97-多核苷酸结合物
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198641A1 (fr) 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition injectable de facteur vii et d'excipients
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
DK3328881T3 (da) 2015-09-08 2019-10-07 Theripion Inc Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder
WO2018136163A2 (fr) 2016-12-09 2018-07-26 Theripion, Inc. Polypeptides de fusion apoa-1 en tandem
EP3655439A1 (fr) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Protéines de liaison à l'antigène se liant à 5t4 et 4-1bb, compositions et procédés associés
WO2019094521A1 (fr) 2017-11-07 2019-05-16 Rani Therapeutics, Llc Préparations de facteurs de coagulation à administrer dans un tissu du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler
KR102476887B1 (ko) 2017-12-20 2022-12-13 하버 바이오메드 (상하이) 컴퍼니 리미티드 Ctla-4에 결합하는 항체 및 이의 용도
CN111801346B (zh) 2017-12-27 2024-08-09 免疫实验室私人有限公司 重组多肽及其使用方法
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
JP2022520886A (ja) * 2019-03-27 2022-04-01 シギロン セラピューティクス， インコーポレイテッド 第ｖｉｉ因子療法のための組成物、デバイス及び方法
WO2021030787A1 (fr) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée et un traitement à la demande
WO2021040610A1 (fr) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Polypeptides recombinants et leurs méthodes d'utilisation
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US20240293504A1 (en) 2020-06-22 2024-09-05 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022178090A2 (fr) 2021-02-19 2022-08-25 Theripion, Inc. Polypeptides de fusion dnase, compositions et méthodes associées
WO2024042148A1 (fr) 2022-08-26 2024-02-29 Stellaris Pharmaceuticals Aps Compositions inhibant l'hémorragie et procédés les impliquant
WO2024148328A2 (fr) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Molécules de liaison pd-l1 et cd40 bispécifiques et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
AU560686B2 (en) * 1982-08-04 1987-04-16 British Technology Group Limited Cloning vehicle dna h-factor ix elements

Also Published As

Publication number Publication date
IE61982B1 (en) 1994-12-14
ES8800343A1 (es) 1987-11-01
IE860995L (en) 1986-10-17
JP2835038B2 (ja) 1998-12-14
JPH0824587B2 (ja) 1996-03-13
JP2726806B2 (ja) 1998-03-11
DK177386A (da) 1986-10-18
CN86102644A (zh) 1987-06-03
DK175616B1 (da) 2004-12-27
HU204556B (en) 1992-01-28
JPS62283A (ja) 1987-01-06
EP0200421B1 (fr) 1993-07-28
US4784950A (en) 1988-11-15
ES554038A0 (es) 1987-11-01
DK177386D0 (da) 1986-04-17
AU5617786A (en) 1986-11-06
AU603983B2 (en) 1990-12-06
DE3688760T2 (de) 1993-10-28
NO175066C (fr) 1994-08-24
DK200401261A (da) 2004-08-20
GR860984B (en) 1986-08-18
HUT43634A (en) 1987-11-30
FI861598A0 (fi) 1986-04-16
FI861598A (fi) 1986-10-18
JP2544090B2 (ja) 1996-10-16
PT82408B (pt) 1988-08-17
JPH07163374A (ja) 1995-06-27
NZ215842A (en) 1988-04-29
NO1996012I1 (no) 1996-10-21
NO175066B (no) 1994-05-16
NO861482L (no) 1986-10-20
DE3688760D1 (de) 1993-09-02
FI100055B (fi) 1997-09-15
JPH07163375A (ja) 1995-06-27
EP0200421A3 (en) 1987-06-03
JPH10117787A (ja) 1998-05-12
NO1996007I1 (no) 1996-06-26
CN1032142C (zh) 1996-06-26
PT82408A (en) 1986-05-01
EP0200421A2 (fr) 1986-11-05
CA1340512C (fr) 1999-04-27
ATE92105T1 (de) 1993-08-15

Similar Documents

Publication Publication Date Title
LU88806I2 (fr) NovoSeven R Eptacog alfa (activated)
AU4814885A (en) Modified tissue plasminogen activator produced by recombinant DNA
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DK72593D0 (da) Rekombinant protein
DE69131292D1 (de) Antikoagulierende proteine
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
KR880013978A (ko) 피브린 분해 단백질
Marcum et al. Species specificity of streptokinase
FI924306A (fi) Foerbaettrat vaevnadslim som framstaellts genom anvaendning av kryofaellning
DE3481417D1 (de) Kontinuierliche, katalytische epoxidation von olefinischen doppelbindungen mit wasserstoffperoxid und ameisensaeure.
ATE277172T1 (de) Rekombinante blutgerinnungsproteasen
ATE105480T1 (de) Thrombin bindende substanz und verfahren zu ihrer herstellung.
ES2067556T3 (es) Vectores de expresion de adn recombinante y compuestos de adn que codifican la actividad isopenicilina n epimerasa (racemasa).
ATE135408T1 (de) Für ein protein mit der fähigkeit zur zusammenwirkung mit dem enhancer des alpha- fetoproteingens kodierende dna
NL960017I2 (nl) Expressie van Factor VIII-activiteit in zoogdiercellen.
DK1392354T3 (da) Anvendelse af alpha-1-antichymotrypsin til fremstillingen af en sammensætning til behandling, forebyggelse eller diagnose af dårligt helende diabetiske sår
ES2056123T3 (es) Clonacion del gen que codifica la enzima isoamilasa y su empleo en la produccion de dicha enzima.
Fořtová et al. Isolation of a fibrinogen-converting enzyme ficozyme from the venom of Bothrops asper by one-step affinity chromatography on Blue Sepharose
Zhong Role of the first epidermal growth factor-like domain in factor IX function.
CANFIELD THE PROTEOLYTIC ACTIVATION AND INACTIVATION OF BOVINE COAGULATION FACTOR V (HEMOSTASIS)
Thorngate Expression of variants of bovine thrombin in Escherichia coli.